MR MEASUREMENT OF TUMOR PH, PO2 & VASCULARITY IN VIVO & RELATED PROJECTS

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是全面了解肿瘤生理学与肿瘤生长、发展和治疗反应的关系。 一些非核磁共振方法，如光学技术正在开发中，然而，我们继续追求我们的MRI努力与测量的氧张力和酶的活化。 我们使用特定酶的氟化底物，并利用19 F化学位移将随着水解而位移的事实，并且不存在19 F背景允许通过NMR对反应进行简单检测。 我们的另一个目标是专注于氧张力和动态响应的干预措施，灌注和跨膜pH值。氧动力学检测使用FREDOM，19 F MRI方法使用六氟苯作为报告分子，我们已经开发了在过去的几年。这使我们能够生成肿瘤氧分压的定量图，并评估局部对干预的反应。最重要的是，我们现在已经表明，伴随干预措施的氧张力的测量变化正确地预测增强的治疗结果（辐射诱导的生长延迟）。通过动态对比增强和BOLD（血氧水平依赖性对比）1H MRI评估肿瘤灌注。 这是一个庞大的团队，在校园内有Vikram Kodibagkar博士，Luis Parada博士和Hanli Liu博士的互动。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this research is to gain a comprehensive understanding of tumor physiology as related to tumor growth, development and response to therapy. A number of nonNMR approaches such as optical techniques are under development, However, we continue to pursue our MRI efforts related to measurement of oxygen tension and enzyme activation. We use fluorinated substrates of specific enzymes and take advantage of the fact that the 19F chemical shift will shift with hydrolysis, and the absence of a 19F background allows simple detection by NMR of the reaction. Our other object is to focus on oxygen tension and the dynamic response to interventions, perfusion and transmembrane pH. Oxygen dynamics are detected using FREDOM, a 19F MRI method using hexafluorobenzene as a reporter molecule, which we have developed over the past several years. This allows us to generate quantitative maps of tumor oxygen tension and to assess local response to interventions. Most significantly, we have now shown that measured changes in oxygen tension accompanying interventions correctly predict enhanced therapeutic outcome (radiation induced growth delay). Tumor perfusion is assessed by dynamic contrast enhancement and BOLD (Blood Oxygen Level Dependant contrast) 1H MRI. This is a large group with interactions across the campus including Dr. Vikram Kodibagkar, Dr. Luis Parada, and Dr. Hanli Liu.